Our professionals

Imagen del Dr. Javier Arbizu Lostao, especialista en Medicina Nuclear de la Clínica Universidad de Navarra. El Dr. Arbizu se dedica preferencialmente a las áreas de Neuroimagen PET y SPECT, y Terapia con Radionúcleidos.

Dr. Javier Arbizu

Director of the Nuclear Medicine Department.
Specialist in Nuclear Medicine.
Primary focus on molecular neuroimaging, theragnostics, and endocrine and neuroendocrine tumors.

Works at: Navarre headquarters
Be part of: Clínica Universidad de Navarra Cancer Center Clínica Universidad de Navarra
INDEX H 41

Professional career

Degree (1985) and PhD (2003) in Medicine and Surgery from the University of Navarra. Specialist trained in the Nuclear Medicine Department of the Clínica Universidad de Navarra. Furthered his studies at Mount Sinai Hospital in New York, the University of Pittsburgh Medical Center (USA), and Hammersmith Hospital in London.

Head of the PET and SPECT imaging area in Neurology, Neuro-oncology, and Endocrinology within the Nuclear Medicine Department at the Clínica Universidad de Navarra. He is also responsible for the Theragnostics area (therapy and diagnosis with radionuclides) in the same department.

Director of the Nuclear Medicine Department since January 2021.

RESEARCH AREAS

  • Demencias: Biomarcadores de imagen PET para el diagnóstico de la enfermedad de Alzheimer y enfermedades neurodegenerativas que cursan con demencia (PET-Amiloide, PET-Tau; PET de Neurodegeneración).
  • Parkinson: Biomarcadores de imagen PET para el diagnóstico precoz y valoración de la progresión de la enfermedad de Parkinson y otros parkinsonismos. Diagnóstico diferencial del síndrome parkinsoniano atípico en fases iniciales. (PET-FDG, PET-FDOPA, PET-Tau).
  • Tumores Cerebrales: Diagnóstico y planificación de la Cirugía y de la Radioterapia de gliomas y otros tumores cerebrales (PET-aminoácidos).
  • Teragnosis con péptidos marcados con radionúclidos en tumores Neuroendocrinos (177Lu/68Ga-DOTA TATE), y cáncer de próstata (177Lu/68Ga-PSMA).

AREAS OF INTEREST

  • Dementia: PET imaging biomarkers for the diagnosis of Alzheimer’s disease and other neurodegenerative disorders associated with dementia (PET-Amyloid, PET-Tau, PET-Neurodegeneration).
  • Parkinson’s disease: PET imaging biomarkers for the early diagnosis and assessment of disease progression in Parkinson’s disease and other parkinsonian syndromes. Differential diagnosis of atypical parkinsonian syndromes in early stages (PET-FDG, PET-FDOPA, PET-Tau).
  • Brain tumors: Diagnosis and planning of surgery and radiotherapy for gliomas and other brain tumors (PET–amino acids).
  • Theragnostics with radionuclide-labeled peptides in neuroendocrine tumors (177Lu/68Ga-DOTA TATE) and prostate cancer (177Lu/68Ga-PSMA).

Activity

In teaching

  • Profesor Titular de la Facultad de Medicina de la Universidad de Navarra (acreditado por la Agencia Nacional de Evaluación de la Calidad y Acreditación).
  • Responsable del Departamento de Medicina Nuclear.
  • Director de varias tesis doctorales.
  • Profesor de cursos de Doctorado y programas Máster en diversas universidades españolas.

In research

  • Has published more than 115 articles in international peer-reviewed scientific journals.
  • Has contributed to 12 national and international specialty books.
  • Invited speaker at national and international conferences, with more than 150 presentations delivered.
  • Principal Investigator in recent years in three competitive national projects (Health Research Fund and Health Technology Development, Carlos III Institute) and five privately funded projects (clinical trials, national and international foundations).
  • Holds four officially recognized six-year research periods (sexenios) awarded by the National Commission for the Evaluation of Research Activity of the National Agency for Quality Assessment and Accreditation (Ministry of Education).
Imagen de un icono azul con un documento certificado.

Scientific Organizations

  • Member of the Editorial Board of the *European Journal of Nuclear Medicine and Molecular Imaging*, *Clinical and Translational Imaging*, *Diagnostics*, and the *Revista Española de Medicina Nuclear e Imagen Molecular*.
  • Expert for the Research Evaluation Agency, Ministry of Science and Innovation (Spain).
  • Chairman of the Board of Directors of the Brain Imaging Council, Society of Nuclear Medicine (USA) (2019–2023).
  • Vice-Chairman of the Neuroimaging Committee, European Association of Nuclear Medicine and Molecular Imaging (2017–2019).
  • Member of the Executive Committee and General Board, Spanish Society of Nuclear Medicine and Molecular Imaging (2013–2018).
  • Coordinator of the Neuroimaging Group, Spanish Society of Nuclear Medicine and Molecular Imaging (2011–2018).